Drugs / BLOOD CELLS, RED
BLOOD CELLS, RED
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04814264 | Jan → May 2022 | blood group incompatibility | McMaster University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02724605 | Jan 2016 → Jun 2017 | — | Abdelrady S Ibrahim, MD | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT01977547 | Jan 2014 → Dec 2018 | anemia | Washington University School of Medicine | Completed | Missed primary |
| Phase not applicable1 trial | ||||||
| — | NCT04591574 | Sep 2020 → Jun 2025 overdue | anemia | University of Edinburgh | Active not recruiting | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT04149171 Comparator | Sep 2018 → Dec 2020 | — | Cristina Martinez | Completed | No outcome recorded |
| Phase 3 | NCT04704869 Background | Jan 2017 → Dec 2021 | — | Bryan Cotton | Completed | Missed primary |
| — | NCT00470444 Comparator | Dec 2006 → Apr 2009 | — | Unity Health Toronto | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-11-03 | Rigel Pharmaceuticals | Results Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition rigel.com ↗
Additionally, of the late responders who were transfusion dependent for platelets (n=6) or red blood cells (n=9) at baseline, 5 (83%) and 8 (89%), respectively, became transfusion independent. |
| 2023-12-11 | Geron Corporation | Results Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS geron.com ↗ |
| 2023-05-25 | Geron Corporation | Results Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3 geron.com ↗
This abstract describes statistically significant positive efficacy and safety data from the pivotal IMerge Phase 3 clinical trial evaluating the Company’s first-in-class telomerase inhibitor, imetelstat, in lower risk myelodysplastic syndromes (MDS). |
All press releases naming this drug 5 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BLOOD CELLS, RED | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108195 ↗ |
| Known as | Hematocrit | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108195 ↗ |
| Known as | Human red blood cells | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108195 ↗ |
| Known as | RBC | “red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC)” NCT04149171 ↗ |
| Known as | RBCs | “comparing the development of "New or Progressive Multiple Organ Dysfunction Syndrome" (NPMODS) in 1538 critically ill children randomized to either transfusion with RBCs stored...” PMID 30055634 ↗ Jul 2018 |
| Known as | Red Blood Cells | “Patients were randomized to receive either fresh or standard-issue red blood cells.” PMID 31821429 ↗ Dec 2019 |
| Route | Other | “transfusion with RBCs” PMID 30055634 ↗ Jul 2018 |